Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

693
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
693
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

499
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
499
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

379
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
379
Drug Therapy01:28

Drug Therapy

197
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
197
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

603
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
603
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

454
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
454

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.

Molecular psychiatry·2026
Same author

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
Same author

Efficacy and Clinical Relevance of Adjunctive Cariprazine Treatment in Patients with Major Depressive Disorder: Post Hoc Analyses from a Phase III Study.

Neuropsychiatric disease and treatment·2026
Same author

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

International clinical psychopharmacology·2026
Same author

Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.

JAMA network open·2026
Same author

Patient treatment preference as a predictor of clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and nonresponders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026

Related Experiment Video

Updated: Dec 21, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.3K

Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.

Roueen Rafeyan, George I Papakostas, W Clay Jackson

    The Journal of Clinical Psychiatry
    |May 16, 2020
    PubMed
    Summary

    Many patients show inadequate response to antidepressant therapy. Treatment options include augmentation, dose increase, switching antidepressants, or combining therapies, tailored to individual patient needs.

    More Related Videos

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    14.4K
    Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
    07:12

    Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

    Published on: August 2, 2021

    4.0K

    Related Experiment Videos

    Last Updated: Dec 21, 2025

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
    04:29

    Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

    Published on: January 7, 2019

    29.3K
    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    14.4K
    Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
    07:12

    Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

    Published on: August 2, 2021

    4.0K

    Area of Science:

    • Psychiatry and Neurobiology
    • Pharmacology

    Background:

    • Approximately 30%-50% of patients exhibit an insufficient response to standard antidepressant treatments.
    • Managing treatment resistance in depression requires exploring alternative therapeutic strategies.

    Purpose of the Study:

    • To review augmentation and adjunctive strategies for patients with inadequate antidepressant response.
    • To discuss off-label medication options for treatment-resistant depression.

    Main Methods:

    • Review of current clinical practices and literature on antidepressant augmentation.
    • Analysis of atypical antipsychotics, buspirone, stimulants, thyroid hormone, and lithium as adjunctive therapies.

    Main Results:

    • Augmentation with atypical antipsychotics is a key strategy for non-responders.
    • Off-label options like buspirone, stimulants, thyroid hormone, and lithium offer further therapeutic avenues.

    Conclusions:

    • Personalized treatment strategies are crucial for optimizing outcomes in patients with inadequate antidepressant response.
    • Clinicians must consider patient-specific factors like response, tolerability, and disease severity when selecting therapies.